Champions Oncology, Inc.

What they do

The company operates computational and experimental research platforms built around a proprietary bank of approximately 1,500 Patient Derived Xenograft (PDX) models, implanted and expanded in mice. It performs in vivo and ex vivo pharmacology, biomarker and bioinformatics studies that test oncology drugs and drug combinations against those tumors. The associated Datacenter holds roughly 3,500 molecular datasets, 3,000 clinical drug responses, 3,500 in vivo drug responses and about 20,000 public datasets. The same platform underlies its marketed PDX data and oncology research SaaS tools.

Revenue drivers

• Translational Oncology Solutions research services — Studies using the TumorBank and research center for pharmaceutical and biotechnology companies; the 10-K states the company currently derives revenue primarily from research services.
• PDX model data and SaaS data licensing — Sale of PDX model data and oncology research SaaS tools to cancer research scientists; management cited increased data license revenue as a contributor to first-quarter fiscal 2027 growth.
• Novel oncology therapeutics — Discovery and development of novel oncology therapeutics through Corellia, a wholly owned target-discovery subsidiary; this is an investment area rather than a reported revenue driver.

Recent performance

For the first quarter of fiscal 2027 (ended July 31, 2026), revenue was $15.2 million, up 8.8% from $14.0 million a year earlier, driven by higher research services revenue and increased data licensing. Oncology services margin improved to 51% from 43%, and adjusted EBITDA rose to $671,000 from $59,000. Cost of oncology revenue fell 5.8% to $7.5 million, while sales and marketing expense rose 66.6% to $3.1 million. The quarter produced a net loss of $426,000 versus a $466,000 loss a year earlier, and net cash used in operations was approximately $492,000. The company ended the quarter with about $4.4 million of cash and no debt.

Strategy

Management says it is investing in its commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives. The stated focus is broadening the data business across a larger customer base while keeping expense discipline and converting revenue growth into improved profitability. Increasing the number of PDX models in the TumorBank is described as an important strategic effort requiring significant research and development resources. Discovery and development of novel oncology therapeutics continues through the Corellia subsidiary.

Risks

• History of losses and capital needs — The company reported a fiscal 2026 net loss of approximately $1.2 million, an accumulated deficit of approximately $81.1 million and cash used in operations of approximately $4.5 million.
• Liquidity runway — At July 31, 2026 the company held $4.4 million of cash against $28.8 million of liabilities and $3.9 million of shareholder equity; the 10-K states cash on hand plus expected operating cash flows are adequate only through at least August 2027.
• Concentration in research services revenue — The 10-K notes the company currently derives revenue primarily from research services while it pursues drug discovery business units, leaving results exposed to demand from biopharmaceutical customers.
• Rising commercial and development costs — Sales and marketing expense rose 66.6% year over year to $3.1 million and research and development rose 12.6% to $2.3 million, so revenue growth must outpace that spending to improve profitability.

Outlook

Management points to improved study execution and conversion in core research services, plus increased commercial activity around its data offerings, as the basis for broader customer reach. The stated priorities are revenue growth, expense discipline and converting growth into improved profitability. No specific numerical guidance for future periods is provided.